<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2696-130X</journal-id>
<journal-title><![CDATA[Revista mexicana de angiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. angiol.]]></abbrev-journal-title>
<issn>2696-130X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Angiología, Cirugía Vascular y Endovascular A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2696-130X2024000300005</article-id>
<article-id pub-id-type="doi">10.24875/rma.23000007</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[MEK inhibitors in maintenance of a postoperative patient with vasculopathy due to neurofibromatosis type I]]></article-title>
<article-title xml:lang="es"><![CDATA[Inhibidores MEK en mantenimiento de un paciente posoperado, con vasculopatía por neurofibromatosis tipo I]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Turégano]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mondragón-Zamora]]></surname>
<given-names><![CDATA[Jennifer K.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar-Álvarez]]></surname>
<given-names><![CDATA[Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendieta-Azcona]]></surname>
<given-names><![CDATA[Covadonga]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Gutiérrez]]></surname>
<given-names><![CDATA[Juan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marín-Manzano]]></surname>
<given-names><![CDATA[Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Angiology and Vascular Surgery Service  ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario La Paz Pediatric Plastic Surgery Unit Pediatric Surgery Service]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<volume>52</volume>
<numero>3</numero>
<fpage>108</fpage>
<lpage>113</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2696-130X2024000300005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2696-130X2024000300005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2696-130X2024000300005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Vasculopathy in the context of neurofibromatosis type I is challenging, and its management requires a multidisciplinary approach. We describe the case of a 24-year-old girl with NFI and vascular complications who was successfully managed with MEK inhibitors, obtaining clinical stabilization. After left occipital artery embolization prior to surgical resection of an occipital neurofibrom, a left internal carotid artery pseudoaneurysm was detected, requiring open repair that failed, leading to direct ligation due to profuse bleeding. In the immediate postoperative period, during a coughing spell, rupture of the left subclavian artery occurred, which was successfully treated by implanting a 7 × 10 mm Viabahan®. Trametinib (0.5 mg/24 h) was administered, replaced by selumetinib (45 mg every 12 h), both therapies in compassionate use. Selumetinib was effective in stabilizing the development of vascular complications, achieving good control over symptomatology of the patient. Three months after starting treatment with MEK inhibitors, no new events have occurred.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La neurofibromatosis tipo I (NFI) es un trastorno que conduce a una sobreactivación de la vía RAS, asociando anomalías vasculares de mediano y gran vaso, espectro denominado vasculopatía de la NFI. Presentamos el caso de una paciente de 24 años con NFI que tras el intento fallido de reparación de un pseudoaneurisma de la arteria carótida interna, requirió ligadura por sangrado profuso. Durante un acceso de tos, presentó ruptura espontánea de la arteria subclavia izquierda, tratada con éxito implantando un Viabahn® de 7 x 10 mm. En el postoperatorio se inicia trametinib (0.5 mg/24 h), reemplazándose por selumetinib 45 mg cada 12 h por dos meses. Tras el alta hospitalaria, el selumetinib fue eficaz para estabilizar el desarrollo de complicaciones vasculares. A tres meses de iniciado el tratamiento farmacológico, no ha presentado nuevas complicaciones.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Neurofibromatosis]]></kwd>
<kwd lng="en"><![CDATA[Trametinib]]></kwd>
<kwd lng="en"><![CDATA[Selumetinib]]></kwd>
<kwd lng="en"><![CDATA[Vasculopathy]]></kwd>
<kwd lng="en"><![CDATA[Pseudoaneurysm]]></kwd>
<kwd lng="es"><![CDATA[Neurofibromatosis]]></kwd>
<kwd lng="es"><![CDATA[Trametinib]]></kwd>
<kwd lng="es"><![CDATA[Selumetinib]]></kwd>
<kwd lng="es"><![CDATA[Vasculopatía]]></kwd>
<kwd lng="es"><![CDATA[Pseudoaneurisma]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Birch]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Korf]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Tenconi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Niimura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Poyhonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis Type I]]></article-title>
<source><![CDATA[Am J Med Genet]]></source>
<year>2000</year>
<volume>95</volume>
<page-range>108-17</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Arbiser]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gutman]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Huot]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease in neurofibromatosis 1:report of the NF1 cardiovascular task force]]></article-title>
<source><![CDATA[Genet Med]]></source>
<year>2002</year>
<volume>4</volume>
<page-range>105-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insights into the pathogenesis of neurofibromatosis 1 vasculopathy]]></article-title>
<source><![CDATA[Clin Genet]]></source>
<year>2000</year>
<volume>58</volume>
<page-range>341-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reubi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Les vaisseaux et les glandes endocrines dans la neurofibroma-tose:le syndrome sympathicotonique dans le maladie de Reckling-hausen]]></article-title>
<source><![CDATA[Schweiz Z Pathol Bacteriol]]></source>
<year>1944</year>
<volume>7</volume>
<page-range>168-236</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oderich]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Bower]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Gloviczki]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Babovic-Vuksanovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vascular abnormalities in patients with neurofibromatosis syndrome Type I:clinical spectrum, management, and results]]></article-title>
<source><![CDATA[J Vasc Surg]]></source>
<year>2007</year>
<volume>46</volume>
<page-range>475-84</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miyazaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Daisu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoshii]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extracranial vertebral artery aneurysm ruptured into the thoracic cavity with neurofibromatosis Type 1:case report]]></article-title>
<source><![CDATA[Neurosurgery]]></source>
<year>2004</year>
<volume>54</volume>
<page-range>1517-20</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Munschauer]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ruptured internal carotid aneurysm resulting from neurofibromatosis:treatment with intraluminal stent graft]]></article-title>
<source><![CDATA[J Vasc Surg]]></source>
<year>2000</year>
<volume>32</volume>
<page-range>824-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoshida]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tobe]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dissection and rupture of the left subclavian artery presenting as hemothorax in a patient with von Recklinghausen's disease]]></article-title>
<source><![CDATA[Jpn J Thorac Cardiovasc Surg]]></source>
<year>2005</year>
<volume>53</volume>
<page-range>117-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Friedman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality in neurofibromatosis 1:an analysis using U. S. death certificates]]></article-title>
<source><![CDATA[Am J Hum Genet]]></source>
<year>2001</year>
<volume>68</volume>
<page-range>1110-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lugowska]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kose&#322;a-Paterczyk]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kozak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rutkowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trametinib:a MEK inhibitor for management of metastatic melanoma]]></article-title>
<source><![CDATA[Onco Targets Ther]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>2251-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flaherty]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Infante]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Daud]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kefford]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Sosman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<page-range>1694-703</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Eberhart]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Raabe]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2020</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>563-74</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Keam]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selumetinib:first approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>931-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wolters]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Dombi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Whitcomb]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selumetinib in children with inoperable plexiform neurofibromas]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2020</year>
<volume>382</volume>
<page-range>1430-42</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hwang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis Type 1:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2022</year>
<volume>98</volume>
<page-range>46</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anforth]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kefford]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acneiform eruptions:a common cutaneous toxicity of the MEK inhibitor trametinib]]></article-title>
<source><![CDATA[Australas J Dermatol]]></source>
<year>2014</year>
<volume>55</volume>
<page-range>250-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
